{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-011061","form_type":"8-K","ticker":"INFU","cik":"0001337013","company_name":"InfuSystem Holdings, Inc","filed_at":"2024-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.864333+00:00","generated_at":"2026-06-04T19:02:46.635864+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"InfuSystem reports FY2023 record revenue $125.8M, +14%; EPS $0.04; guides FY2024 high-single-digit growth","bullets":["FY2023 net revenue $125.8M (+14% YoY); Patient Services $76.5M (+11%), Device Solutions $49.2M (+20%).","Q4 net revenue $31.8M (+10%); net income $0.1M ($0.00 diluted EPS) vs $0.1M ($0.01) prior year.","Adjusted EBITDA $22.4M (+8%); operating income $4.1M (+147%); net income $0.9M vs $0.0M prior year.","FY2024 guidance: high-single-digit revenue growth; Adjusted EBITDA margin in high-teens (above 17.8%).","Joint venture SI Wound Care (with Sanara MedTech) expected to generate meaningful revenue in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-011061","json":"https://secwatch.observer/filing/0001628280-24-011061.json","markdown":"https://secwatch.observer/filing/0001628280-24-011061.md","text":"https://secwatch.observer/filing/0001628280-24-011061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1337013/000162828024011061/0001628280-24-011061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1337013/000162828024011061/infu-20240314.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T19:02:46.635864+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"138035443947b37539883e6abedb8ff129792e7b","claim":"InfuSystem Holdings, Inc reported fourth quarter and full year ended December 31, 2023 results: revenue Net revenues totaled $125.8 million. Guidance reaffirmed.","evidence_excerpt":"Partners, LLC 602-889-9700 InfuSystem Announces Operational and Financial Results for Fourth Quarter and Full Year 2023 Full Year 2023 vs. Full Year 2022: Record Net Revenues: $125.8 million, a 14% increase Patient Services Revenue: $76.5 million - Device Solutions Revenue: $49.2 million, increases of 11% and 20% Adjusted EBITDA (non-GAAP): $22.4 million, an 8%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1337013/000162828024011061/0001628280-24-011061-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"Net revenues totaled $125.8 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}